A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 in Healthy Subjects

Study identifier:D7960C00001

ClinicalTrials.gov identifier:NCT05384262

EudraCT identifier:2022-002221-10

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Randomized, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD0780 Following Single and Multiple Ascending Dose Administration to Healthy Subjects with or without Elevated LDL-C Levels

Medical condition

Dyslipidemia

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD0780, Placebo, Rosuvastatin

Sex

All

Actual Enrollment

183

Study type

Interventional

Age

18 Years - 55 Years

Date

Study Start Date: 18 May 2022
Primary Completion Date: 14 Jun 2024
Study Completion Date: 14 Jun 2024

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jul 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

PAREXEL

Inclusion and exclusion criteria